

Contact: Russell LaMontagne
Phone: 212-255-5340
E-mail: russell@corinthgroup.com

Shuyuan Zhang Joins VIRxSYS as Senior Director of Production

Gaithersburg, MD - (August 18, 2008) - VIRxSYS Corporation announced today that Shuyuan Zhang, PhD, has joined the company as Senior Director of Production. Zhang will focus on the development and late stage GMP manufacture of lentiviral vectors and ex vivo patient CD4 T cell transduction and expansion for HIV treatment.

The Company's first application of its novel lentiviral vector technology is an HIV gene therapy, VRX496, which has completed Phase I and II clinical trials. The Phase II results provided researchers with a better understanding about how VRX496 operates. VRX496 binds to the RNA of HIV, changing the genetics and biology of the virus, including the molecular diversity of HIV and the replicative fitness. VIRxSYS currently has underway a preclinical investigational prophylactic HIV vaccine, VRX1023, that aims to protect individuals against new infections. Zhang will oversee the development and GMP manufacture of lentiviral vectors for the expansion of HIV treatment.

"We are extremely fortunate to have Dr. Zhang as part of our team. He has extensive experience in gene therapy, specifically in process development and manufacture of retroviral vectors for Phase 3 trials and eventual commercialization," said Dr. Riku Rautsola, President and CEO of VIRxSYS. "We recognize the challenges of our industry and believe that Dr. Zhang's experience will provide a great advantage to our company."

Dr. Shuyuan Zhang has more than 15 years process development and GMP manufacture experience working in the gene therapy industry since graduation from the University of Surrey, UK in 1993. Prior to joining VIRxSYS, he assumed increasingly more important positions working at Genetic Therapy Inc., Introgen Therapeutics, Inc., and Targeted Genetics Corp. on process development and GMP manufacture of retroviral vector, adenoviral vector, adeno-associated viral vector and non-viral liposomal vector products for human gene therapy applications. Most recently he held the position of Director of Process Development and Analytical Services at Introgen Therapeutics, Inc. in Houston, Texas. He was an active member of a team in the development and advancement of ADVEXIN[®] to completion of a Phase III clinical study and the authorization of the CTD document for a BLA submission to the FDA and Marketing Authorization Application (MAA) to the EMEA. He is experienced in the process, facility/equipment and analytical method validations for manufacture of late stage gene therapy products.

Dr. Zhang is the inventor of more than five issued US patents covering manufacturing processes for retroviral vectors and adenoviral vectors for human gene therapy applications.

About VIRxSYS

Founded in 1998, VIRxSYS is a private biotechnology company that focuses on the development of a novel lentiviral vector platform technology for the treatment of serious diseases such as HIV/AIDS and cancer. The Company has exclusively licensed its patented, proprietary technology platform from The Johns Hopkins University (JHU) in Baltimore, Maryland where the original research was conducted. The Company also has been issued additional patents relating to the application and manufacture of the technology. More information regarding VIRxSYS can be found at www.virxsys.com. Details for the Phase II study may be found at the NIH clinical trials website at clinicaltrials.gov/show/NCT00131560.

###